课题基金 / 基金详情

Markers and therapeutic strategies for overcoming chemoradiotherapy resistance

Markers and therapeutic strategies for overcoming chemoradiotherapy resistance
克服放化疗耐药性的标志物和治疗策略
批准号：
8332452
负责人：
John V. Heymach
金额：
$29.05万
依托单位：
UNIVERSITY OF TX MD ANDERSON CAN CTR
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
项目状态：
已结题
起止时间：
2011-09-26 至 2016-07-31
来源：
https://reporter.nih.gov/project-details/8332452
关键词：
AddressAntibodiesCandidate Disease GeneCetuximabCisplatinClinicalCollaborationsDNA Repair PathwayDataData SetDatabasesDiseaseDistant MetastasisDistressDouble Strand Break RepairEpidermal Growth Factor ReceptorEpidermal Growth Factor Receptor Tyrosine Kinase InhibitorFormalinFundingGene ExpressionGene Expression ProfileGrantHead and Neck Squamous Cell CarcinomaHuman PapillomavirusImmunohistochemistryIn VitroIndividualInstructionLungMalignant Epithelial CellMesenchymalMeta-AnalysisOutcomeParaffin EmbeddingPathway interactionsPatientsPhasePhase III Clinical TrialsPhysiciansPopulationPostoperative PeriodPrognostic MarkerProteinsProteomicsRadiation Therapy Oncology GroupRandomizedRegimenRelapseResearch PersonnelResistanceSignal PathwaySignal TransductionSocietiesSourceSpecialized Program of Research ExcellenceSpecimenTelomeraseTestingTherapeuticTissuesToxic effectValidationXRCC5 genebasecandidate markerclinical applicationclinical practicecombatdesignepithelial to mesenchymal transitionexperiencegenome-wideimprovedin vitro Modelnovelnovel markerpre-clinicalpreferenceprogramsrandomized trialreceptor expressionresistance mechanismresponseresponse markertherapeutic targettumorworking group

项目成果

John V. Heymach的其他基金

相似基金

相关文献

期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting Lung Cancer Vulnerabilities
  • 批准号：
    10816969
  • 项目类别：
  • 资助金额：
    $4.56万
  • 财政年份：
    2023
  • 负责人：
    John V. Heymach
  • 依托单位：
    UT SOUTHWESTERN MEDICAL CENTER
Molecular features impacting drug resistance in atypical EGFR exon 18 and exon 20 mutant non-small cell lung cancers and the development of novel mutant-selective inhibitors
Molecular features impacting drug resistance in atypical EGFR exon 18 and exon 20 mutant non-small cell lung cancers and the development of novel mutant-selective inhibitors
Therapeutic strategies against EGFR exon 20 mutant lung cancer
海外基金